Edwards Lifesciences Other Operating Income decreased by 0.7% to $14.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 25.7%, from $19.10M to $14.20M.
mu_other_operating_income_expense_net| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$22.40M | $22.70M | $19.10M | $21.30M | $12.50M | $14.30M | $14.20M |
| QoQ Change | — | — | — | — | — | — | — | — | — | +201.3% | -15.9% | +11.5% | -41.3% | +14.4% | -0.7% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | — | +155.8% | -37.0% | -25.7% |